Dai ichi Life Insurance Company Ltd Sells 1,308 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Dai ichi Life Insurance Company Ltd cut its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 45.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,585 shares of the biotechnology company’s stock after selling 1,308 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Axon Enterprise were worth $409,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of AXON. BKM Wealth Management LLC purchased a new stake in shares of Axon Enterprise during the fourth quarter valued at approximately $32,000. Key Financial Inc boosted its stake in Axon Enterprise by 367.6% during the 4th quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 125 shares during the last quarter. Lindbrook Capital LLC increased its holdings in shares of Axon Enterprise by 43.3% in the 4th quarter. Lindbrook Capital LLC now owns 172 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 52 shares in the last quarter. Rakuten Securities Inc. purchased a new position in shares of Axon Enterprise in the fourth quarter worth $48,000. Finally, Principal Securities Inc. bought a new position in shares of Axon Enterprise during the fourth quarter valued at $49,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on AXON. Robert W. Baird lifted their price objective on Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, February 22nd. JMP Securities restated a “market outperform” rating and issued a $375.00 price target on shares of Axon Enterprise in a research note on Tuesday, May 7th. William Blair reissued an “outperform” rating on shares of Axon Enterprise in a report on Wednesday, April 24th. Morgan Stanley upped their price target on shares of Axon Enterprise from $285.00 to $310.00 and gave the company an “equal weight” rating in a research report on Friday, April 26th. Finally, Barclays raised their price objective on shares of Axon Enterprise from $308.00 to $381.00 and gave the stock an “overweight” rating in a report on Wednesday, May 8th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average price target of $335.27.

Axon Enterprise Price Performance

AXON stock traded up $5.64 during mid-day trading on Friday, hitting $285.63. The company had a trading volume of 411,002 shares, compared to its average volume of 616,556. The company has a 50-day moving average price of $306.23 and a 200 day moving average price of $274.04. Axon Enterprise, Inc. has a 12-month low of $175.37 and a 12-month high of $329.87. The company has a market capitalization of $21.56 billion, a price-to-earnings ratio of 83.52 and a beta of 0.91. The company has a quick ratio of 2.55, a current ratio of 2.91 and a debt-to-equity ratio of 0.37.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.20. The company had revenue of $460.74 million during the quarter, compared to analyst estimates of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The firm’s revenue was up 34.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.51 earnings per share. On average, research analysts anticipate that Axon Enterprise, Inc. will post 2.35 earnings per share for the current year.

Insider Buying and Selling

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 43,668 shares of the stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $309.94, for a total transaction of $13,534,459.92. Following the completion of the transaction, the insider now owns 189,719 shares in the company, valued at $58,801,506.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Jeri Williams sold 308 shares of the business’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the completion of the transaction, the director now owns 1,607 shares in the company, valued at approximately $498,282.49. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeffrey C. Kunins sold 43,668 shares of the business’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $309.94, for a total transaction of $13,534,459.92. Following the completion of the transaction, the insider now directly owns 189,719 shares of the company’s stock, valued at approximately $58,801,506.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 87,976 shares of company stock worth $27,268,201. Insiders own 6.10% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.